Abelacimab Biosimilar – Anti-F11 mAb – Research Grade from ProteoGenix; catalogue PX-TA1522; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Abelacimab Biosimilar is a monoclonal antibody (mAb) that specifically targets Factor XI (FXI) in the blood coagulation cascade. It is a biosimilar version of the anti-FXI mAb, which is a recombinant humanized immunoglobulin G1 (IgG1) antibody. The antibody is produced using recombinant DNA technology and has a molecular weight of approximately 150 kDa.
The structure of Abelacimab Biosimilar consists of two identical heavy chains and two identical light chains, connected by disulfide bonds. Each chain contains variable and constant regions, with the variable regions responsible for binding to FXI. The constant regions, on the other hand, determine the antibody’s effector functions, such as complement activation and antibody-dependent cellular cytotoxicity (ADCC).
Abelacimab Biosimilar binds specifically to FXI, a serine protease involved in the amplification of the blood clotting process. FXI is activated upon vascular injury and forms a complex with Factor XII, leading to the activation of Factor IX and subsequent formation of a blood clot. By targeting FXI, Abelacimab Biosimilar prevents the formation of this complex, thereby inhibiting the blood clotting process.
In addition to its inhibitory activity, Abelacimab Biosimilar also has effector functions that contribute to its therapeutic effects. It can activate the complement system, leading to the lysis of target cells, and also induce ADCC, which involves the destruction of target cells by immune cells.
Abelacimab Biosimilar is primarily used as a therapeutic agent for the prevention and treatment of thrombotic disorders. Thrombosis, the formation of blood clots, can lead to serious conditions such as heart attack, stroke, and pulmonary embolism. By inhibiting FXI, Abelacimab Biosimilar can help prevent the formation of blood clots and reduce the risk of these conditions.
Abelacimab Biosimilar has shown promising results in clinical trials, demonstrating its effectiveness in preventing and treating thrombotic events. It has also been studied for its potential use in other conditions, such as hemophilia and cancer, where FXI has been implicated.
Antibody biosimilars, like Abelacimab Biosimilar, are becoming increasingly important in the field of biopharmaceuticals. They are highly similar versions of existing monoclonal antibodies, with comparable efficacy, safety, and quality. Biosimilars offer a more affordable alternative to their originator products, making them more accessible to patients.
Factor XI is a promising therapeutic target for the prevention and treatment of thrombotic disorders. Unlike other components of the blood coagulation cascade, FXI deficiency does not result in bleeding disorders, making it an attractive target for anticoagulant therapy. Inhibiting FXI also has the potential to reduce the risk of bleeding associated with current anticoagulant therapies, such as warfarin.
In conclusion, Abelacimab Biosimilar is a biosimilar version of the anti-FXI mAb, with a specific structure and activity that makes it a promising therapeutic agent for the prevention and treatment of thrombotic disorders. Its application extends beyond this, with potential use in other conditions and as an affordable alternative to originator products. As the development of antibody biosimilars continues to grow, the therapeutic target of Factor XI will likely gain even more importance in the field of biopharmaceuticals.
ProteoGenix catalogue number PX-TA1522. For research use only.
Target: Abelacimab Biosimilar – Anti-F11 mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Abelacimab Biosimilar – Anti-F11 mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
